4.6 Article

Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes

Journal

JACC-CARDIOVASCULAR IMAGING
Volume 5, Issue 3, Pages S42-S52

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcmg.2012.01.008

Keywords

diabetes mellitus; metabolic syndrome; plaque composition; prognosis; radiofrequency intravascular ultrasound

Funding

  1. Medicines Company
  2. Novo Nordisk
  3. Abbott Vascular
  4. Amylin Pharmaceuticals
  5. Boston Scientific
  6. Volcano Corporation
  7. Terumo Medical
  8. Abbott
  9. Adamed
  10. AstraZeneca
  11. Biotronik
  12. Balton
  13. Bayer
  14. BioMatrix
  15. Boehringer Ingelheim
  16. Bristol-Myers Squibb
  17. Cordis
  18. Cook
  19. Eli Lilly
  20. EuroCor
  21. Glaxo
  22. Invatec
  23. Medtronic
  24. MSD
  25. Nycomed
  26. Orbus-Neich
  27. Possis
  28. Promed
  29. Sanofi-Aventis
  30. Siemens
  31. Solvay
  32. Terumo
  33. Tyco
  34. InfraReDx
  35. BBraun

Ask authors/readers for more resources

OBJECTIVES The goal of this study was to characterize the extent and composition of coronary atherosclerosis in patients with diabetes mellitus or the metabolic syndrome (Met Syn) presenting with acute coronary syndromes (ACS). BACKGROUND Diabetes and Met Syn patients have increased rates of major adverse cardiac events (MACE), yet a systematic description of nonculprit lesions for these high-risk groups is incomplete. METHODS In the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study, ACS patients underwent 3-vessel quantitative coronary angiography, grayscale, and radiofrequency intravascular ultrasound after successful percutaneous coronary intervention (PCI). Subsequent MACE (cardiac death or arrest, myocardial infarction, or rehospitalization for unstable or progressive angina) were adjudicated to the originally treated culprit versus untreated nonculprit lesions in 3 patient groups: 1) diabetes; 2) Met Syn; and 3) neither. Median length of follow-up was 3.4 years. RESULTS Of 673 patients, 119 (17.7%) had diabetes and 239(35.5%) had Met Syn. The cumulative 3-year MACE rate was 29.4% in patients with diabetes, 21.3% with Met Syn, and 17.4% with neither (p = 0.03). MACE adjudicated to untreated nonculprit lesions occurred in 18.7%, 11.7%, and 9.7% of patients, respectively (p = 0.06). Nonculprit lesions in diabetes and Met Syn patients were longer and had greater plaque burden, smaller lumen areas, with greater necrotic core and calcium content Diabetes and Met Syn patients with future MACE had greater necrotic core and calcification compared with the normal cardiometabolic group. CONCLUSIONS In this PCI ACS population, patients with diabetes and Met Syn had higher 3-year MACE rates. Lesion length, plaque burden, necrotic core, and calcium content were significantly greater among nonculprit lesions of patients with diabetes and Met Syn, but only necrotic core and calcium were significantly greater in the nonculprit lesions of patients with a future MACE in this exploratory analysis. (I Am Coll Cardiol Img 2012;5:S42-52) (C) 2012 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available